Regulus Therapeutics Announces Timing for First Quarter 2022 Financial Results Webcast and Conference Call

SAN DIEGO, May 5, 2022 /PRNewswire/ — Regulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs (the “Company” or “Regulus”), today announced that it will report its first quarter 2022…

Click here to view original post